Novartis AG ADR (NVS)vsPACS Group, Inc. (PACS)
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
PACS
PACS Group, Inc.
$33.59
-0.12%
HEALTHCARE · Cap: $5.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 970% more annual revenue ($56.58B vs $5.29B). NVS leads profitability with a 23.9% profit margin vs 3.6%. PACS appears more attractively valued with a PEG of 1.00. PACS earns a higher WallStSmart Score of 58/100 (C).
NVS
Buy51
out of 100
Grade: C-
PACS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Margin of Safety
+72.9%
Fair Value
$144.37
Current Price
$33.59
$110.78 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Earnings expanding 57.2% YoY
Every $100 of equity generates 23 in profit
Growing faster than its price suggests
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Moderate valuation
3.6% margin — thin
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PACS
The strongest argument for PACS centers on EPS Growth, Return on Equity, PEG Ratio. Revenue growth of 12.4% demonstrates continued momentum. PEG of 1.00 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : PACS
The primary concerns for PACS are P/E Ratio, Profit Margin, Free Cash Flow. Debt-to-equity of 4.93 is elevated, increasing financial risk. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a declining stock while PACS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
PACS is growing revenue faster at 12.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
PACS scores higher overall (58/100 vs 51/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →PACS Group, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
PACS Group, Inc. is a prominent technology solutions provider dedicated to improving operational efficiency across diverse industries through innovative software and hardware systems. The company emphasizes research and development, positioning itself to leverage emerging technological trends and drive digital transformation. With robust strategic partnerships and a significant market presence, PACS Group is well-equipped to enhance its competitive advantage, making it an attractive investment opportunity for institutional investors seeking growth in the rapidly evolving technology landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?